BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2024-04

185 industry Phase 2/3 trial readout(s) and 47 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2024-03 | 2024-05 →

FDA decision events

DateEventStatusCompanyDrugSource
2024-04-02FDA approvalapprovedVANDA PHARMS INC VNDAFANAPTApproved 2024-04-02: FANAPT (NDA022192 SUPPL23)
2024-04-03FDA approvalapprovedEISAI INCLENVIMAApproved 2024-04-03: LENVIMA (NDA206947 SUPPL30)
2024-04-03FDA approvalapprovedISTXZEVTERAApproved 2024-04-03: ZEVTERA (NDA218275 ORIG1)
2024-04-03FDA approvalapprovedSUN PHARMA GLOBALILUMYAApproved 2024-04-03: ILUMYA (BLA761067 SUPPL18)
2024-04-04FDA approvalapprovedNOVA LABS LTD NVMIXROMIApproved 2024-04-04: XROMI (NDA216593 ORIG1)
2024-04-05Complete response lettercomplete responseAccord BioPharma Inc.INTPSCRL 2024-04-05: Accord BioPharma Inc. BLA 761147 (INTPS)
2024-04-05FDA approvalapprovedVIIV HLTHCAREDOVATOApproved 2024-04-05: DOVATO (NDA211994 SUPPL18)
2024-04-05FDA approvalapprovedVIIV HLTHCAREDOVATOApproved 2024-04-05: DOVATO (NDA211994 SUPPL19)
2024-04-05FDA approvalapprovedASTRAZENECA AB AZNFASENRAApproved 2024-04-05: FASENRA (BLA761070 SUPPL20)
2024-04-05FDA approvalapprovedREGENERON PHARMACEUTICALS REGNLIBTAYOApproved 2024-04-05: LIBTAYO (BLA761097 SUPPL23)
2024-04-05FDA approvalapprovedDAIICHI SANKYOENHERTUApproved 2024-04-05: ENHERTU (BLA761139 SUPPL28)
2024-04-10FDA approvalapprovedELI LILLY AND CO LLYRETEVMOApproved 2024-04-10: RETEVMO (NDA218160 ORIG1)
2024-04-12FDA AdComheldAdCom 2024-04-12: Oncologic Drugs Advisory Committee
2024-04-12Complete response lettercomplete responseGan & Lee PharmaceuticalsCRL 2024-04-12: Gan & Lee Pharmaceuticals BLA 761356
2024-04-12FDA approvalapprovedNOVARTIS NVSENTRESTO SPRINKLEApproved 2024-04-12: ENTRESTO SPRINKLE (NDA218591 ORIG1)
2024-04-12FDA approvalapprovedNOVARTIS PHARMS CORP NVSENTRESTOApproved 2024-04-12: ENTRESTO (NDA207620 SUPPL25)
2024-04-16Complete response letterapproved sinceAbeona Therapeutics, Inc. ABEOCRL 2024-04-16: Abeona Therapeutics, Inc. BL 125807
2024-04-16FDA approvalapprovedALVOTECH USA INC ALVOSELARSDIApproved 2024-04-16: SELARSDI (BLA761343 ORIG1)
2024-04-17Complete response lettercomplete responseAccord Healthcare Inc.CRL 2024-04-17: Accord Healthcare Inc. NDA 218762
2024-04-17FDA approvalapprovedLUMICELLLUMISIGHTApproved 2024-04-17: LUMISIGHT (NDA214511 ORIG1)
2024-04-18FDA approvalapprovedHOFFMANN-LA ROCHEALECENSAApproved 2024-04-18: ALECENSA (NDA208434 SUPPL15)
2024-04-18FDA approvalapprovedTAKEDA PHARMS USA TAKENTYVIOApproved 2024-04-18: ENTYVIO (BLA761359 ORIG1)
2024-04-19Complete response lettercomplete responseXbrane Biopharma ABWe have completed our review of this application, as amendedCRL 2024-04-19: Xbrane Biopharma AB BLA 761187 (We have completed our review of this application, as amended)
2024-04-19Complete response lettercomplete responseDr. Reddy’s Laboratories SACRL 2024-04-19: Dr. Reddy’s Laboratories SA BLA 761376
2024-04-19FDA approvalapprovedBAUSCH AND LOMB INC BLCOLUMIFY PRESERVATIVE FREEApproved 2024-04-19: LUMIFY PRESERVATIVE FREE (NDA218424 ORIG1)
2024-04-19FDA approvalapprovedSCIENTURE SCNXREZENOPYApproved 2024-04-19: REZENOPY (NDA215487 ORIG1)
2024-04-22FDA approvalapprovedALTOR BIOSCIENCE, LLC, AN INDIRECT WHOLLY-OWNED SUANKTIVAApproved 2024-04-22: ANKTIVA (BLA761336 ORIG1)
2024-04-23FDA approvalapprovedDAY ONE BIOPHARMSOJEMDAApproved 2024-04-23: OJEMDA (NDA218033 ORIG1)
2024-04-23FDA approvalapprovedDAY ONE BIOPHARMSOJEMDAApproved 2024-04-23: OJEMDA (NDA217700 ORIG1)
2024-04-23FDA approvalapprovedAAA USA INCLUTATHERAApproved 2024-04-23: LUTATHERA (NDA208700 SUPPL31)
2024-04-24FDA approvalapprovedGILEAD SCIENCES INC GILDBIKTARVYApproved 2024-04-24: BIKTARVY (NDA210251 SUPPL19)
2024-04-24FDA approvalapprovedNOVARTIS NVSVIJOICEApproved 2024-04-24: VIJOICE (NDA215039 SUPPL2)
2024-04-24FDA approvalapprovedNOVARTIS NVSVIJOICEApproved 2024-04-24: VIJOICE (NDA218466 ORIG1)
2024-04-24FDA approvalapprovedALEMBIC THERAPPIVYAApproved 2024-04-24: PIVYA (NDA216483 ORIG1)
2024-04-24FDA approvalapprovedBAXTER HLTHCARE CORP BAXCLINOLIPID 20%Approved 2024-04-24: CLINOLIPID 20% (NDA204508 SUPPL22)
2024-04-25FDA approvalapprovedAMGEN INC AMGNOTEZLAApproved 2024-04-25: OTEZLA (NDA205437 SUPPL13)
2024-04-25FDA approvalapprovedACCORD BIOPHARMA INC.HERCESSIApproved 2024-04-25: HERCESSI (BLA761346 ORIG1)
2024-04-26FDA approvalapprovedX4 PHARMSXOLREMDIApproved 2024-04-26: XOLREMDI (NDA218709 ORIG1)
2024-04-26FDA approvalapprovedABBVIE ABBVRINVOQ LQApproved 2024-04-26: RINVOQ LQ (NDA218347 ORIG1)
2024-04-26FDA approvalapprovedABBVIE ABBVRINVOQApproved 2024-04-26: RINVOQ (NDA211675 SUPPL22)
2024-04-26FDA approvalapprovedABBVIE ABBVRINVOQApproved 2024-04-26: RINVOQ (NDA211675 SUPPL21)
2024-04-29FDA approvalapprovedSEAGENTIVDAKApproved 2024-04-29: TIVDAK (BLA761208 SUPPL7)
2024-04-29FDA approvalapprovedAURINIA AUPHLUPKYNISApproved 2024-04-29: LUPKYNIS (NDA213716 SUPPL4)
2024-04-30FDA approvalapprovedNEUROCRINE NBIXINGREZZA SPRINKLEApproved 2024-04-30: INGREZZA SPRINKLE (NDA218390 ORIG1)
2024-04-30FDA approvalapprovedHOFFMAN-LA ROCHEMIRCERAApproved 2024-04-30: MIRCERA (BLA125164 SUPPL89)
2024-04-30FDA approvalapprovedBOEHRINGER INGELHEIMCYLTEZOApproved 2024-04-30: CYLTEZO (BLA761058 SUPPL26)
2024-04-30FDA approvalapprovedSUMITOMO PHARMA AMMYFEMBREEApproved 2024-04-30: MYFEMBREE (NDA214846 SUPPL7)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2024-04 est.P2OncoSec Medical IncorporatedNCT03567720 Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBCTriple Negative Breast Cancerunknown65
2024-04 est.P2Ascentage Pharma Group Inc. AAPGNCT03883100 A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationChronic Myeloid Leukemia - Accelerated Phaseunknown23
2024-04 est.P3Rigel Pharmaceuticals RIGLNCT04138927 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaWarm Antibody Autoimmune Hemolytic Anemiaenrolling by invitation90
2024-04 est.P2AC Immune SA ACIUNCT04373616 A Study of ACI-24 in Adults With Down SyndromeDown Syndromewithdrawn
2024-04 est.P2/P3Sinocelltech Ltd.NCT04560894 SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaHepatocellular Carcinomaunknown405
2024-04 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05284994 TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerNonsmall-cell Lung Cancerunknown160
2024-04 est.P1/P2BiOneCure Therapeutics Inc.NCT05320588 A Study in Patients With Advanced CancersAdvanced Cancer; Advanced Solid Tumor; Cancer; Oncologyrecruiting332
2024-04 est.P2Abalonex, LLCNCT06096415 Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain InjuryTraumatic Brain Injury; Cerebral Edemaunknown45
2024-04-01P2Allarity Therapeutics ALLRNCT03562832 Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRPMetastatic Breast Cancercompleted20
2024-04-01P3Chipscreen Biosciences, Ltd.NCT04830813 Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung CancerSmall Cell Lung Cancercompleted184
2024-04-01P2RyCarma Therapeutics, Inc.NCT05122975 Treatment of an Inherited Ventricular ArrhythmiaCatecholaminergic Polymorphic Ventricular Tachycardia Type 1terminated8
2024-04-01P1/P2Avenge Bio, IncNCT05538624 A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the OvaryNeoplasm, Ovarian; Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer; Adenocarcinoma Ovary; Seterminated14
2024-04-01P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05628103 A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current AntipSchizophreniacompleted101
2024-04-01P3TJ Biopharma Co., Ltd.NCT05709093 A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With HMyelodysplastic Syndromes(MDS)terminated10
2024-04-01P3Novavax NVAXNCT05973006 Phase 3 Adolescent Study for SARS-CoV-2 rS Variant VaccinesCOVID-19completed400
2024-04-01 est.P2CannaMore BiotechsNCT06353828 Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis PatientsUlcerative Colitisunknown45
2024-04-01P2Soterios LtdNCT06402630 A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderAlopecia Areatacompleted158
2024-04-02P3Takeda TAKNCT04075825 Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal FistulaCrohn's Disease; Complex Perianal Fistulacompleted150
2024-04-02P2Redx Pharma LtdNCT04907539 A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, ColorectaColorectal Cancercompleted25
2024-04-02P2Hope Biosciences Research FoundationNCT05126563 Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 SyndromePost COVID-19 Syndromecompleted79
2024-04-02P3Janssen Research & Development, LLCNCT05528510 A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative ColitisColitis, Ulcerativeactive not recruiting418
2024-04-02P1/P2Sanofi Pasteur, a Sanofi Company SNYNCT05650554 Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and OlderInfluenza Immunizationcompleted682
2024-04-02P3Novartis Pharmaceuticals NVSNCT05888103 Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.Primary Hypercholesterolemia or Mixed Dyslipidemiacompleted207
2024-04-03P3Novartis Pharmaceuticals NVSNCT04732117 Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial SpondyloarthritisNon-radiographic Axial Spondyloarthritiscompleted137
2024-04-03P2/P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05149807 Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerPerioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophagterminated81
2024-04-03P3AO GENERIUMNCT05492409 Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP PatientsIdiopathic Thrombocytopenic Purpuracompleted160
2024-04-03P3Changchun GeneScience Pharmaceutical Co., Ltd.NCT05983445 Safety & Efffficacy of Genakumab in Patients With Frequent FlaresAcute Gout Arthritiscompleted313
2024-04-03P3GlaxoSmithKlineNCT06868654 China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone inMultiple Myelomaactive not recruiting72
2024-04-03P3GlaxoSmithKlineNCT06868667 Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and DexamethasoneMultiple Myelomaactive not recruiting24
2024-04-04P1/P2Bristol-Myers Squibb BMYNCT03110107 First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsAdvanced Cancerterminated376
2024-04-04P3Janssen Research & Development, LLCNCT03901963 A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are MinimaMultiple Myelomacompleted200
2024-04-04P1/P2Sanofi SNYNCT04418661 Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesMetastatic Neoplasmterminated65
2024-04-04P1/P2Istari Oncology, Inc.NCT04690699 LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint InhibitorsSolid Tumor; Bladder Cancer; Non-muscle-invasive Bladder Cancerterminated4
2024-04-04P1/P2Intellia Therapeutics NTLANCT05120830 NTLA-2002 in Adults With Hereditary Angioedema (HAE)Hereditary Angioedemaactive not recruiting37
2024-04-04P2Imugene LimitedNCT05311176 A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZONGastric Cancer; Cancer of Stomach; Gastric Adenocarcinoma; Stomach Cancer; Stomach Adenocarcinoma; Gterminated7
2024-04-04P1/P2AskBio France, SAS, a subsidiary of AskBio Inc.NCT05541627 A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's DiseaseHuntington Diseaseactive not recruiting5
2024-04-04P2AstraZeneca AZNNCT05638737 A Study in Participants With Non-cirrhotic NASH With FibrosisNon-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosiscompleted112
2024-04-05P3Sun Pharmaceutical Industries LimitedNCT03897075 Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail PsoriasisChronic Plaque Psoriasis; Moderate to Severe Nail Psoriasiscompleted99
2024-04-05P2Gyroscope Therapeutics LimitedNCT04437368 EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005Dry Age-related Macular Degenerationterminated98
2024-04-05P3Teva Pharmaceuticals USANCT04976192 Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaChronic Urticariacompleted608
2024-04-05P2Aviceda Therapeutics, Inc.NCT06181227 A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular EdemaDiabetic Macular Edema; Diabetic Retinopathyterminated21
2024-04-06P3Merck Sharp & Dohme LLC MRKNCT04772534 Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)Papillomavirus Infectionscompleted314
2024-04-06 est.P3Sobi, Inc.NCT05046327 Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 MonthsImmune Thrombocytopeniawithdrawn
2024-04-06P3Vanda Pharmaceuticals VNDANCT05903924 Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion SicknessMotion Sicknesscompleted316
2024-04-08P3UCB BIOSCIENCES GmbHNCT01550003 Pediatric Arthritis Study of Certolizumab PegolPolyarticular-course Juvenile Idiopathic Arthritis (JIA)completed193
2024-04-08P1/P2Merck Sharp & Dohme LLC MRKNCT03179436 Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)Advanced Solid Tumorscompleted415
2024-04-08P3AB2 Bio Ltd.NCT03512314 Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label ExtensionXIAP Deficiency; NLRC4-MAScompleted11
2024-04-08P2Sun Pharma Advanced Research Company LimitedNCT03655236 PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706Early Parkinson Diseaseterminated513
2024-04-08P3Corcept Therapeutics CORTNCT03697109 A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing SyndromeCushing Syndromecompleted152
2024-04-08P3CSL BehringNCT03744910 Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant RecipientsAntibody-mediated Rejectionterminated194
2024-04-08P2Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05221502 Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TBPulmonary TBcompleted122
2024-04-08P1/P2AnnJi Pharmaceutical Co., Ltd.NCT05517603 A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In PatientsSpinal and Bulbar Muscular Atrophy; Kennedy's Diseasecompleted25
2024-04-08P3CSPC Ouyi Pharmaceutical Co., Ltd.NCT07239765 A Study to Evaluate the Safety, Efficacy, and PPK of ABCD in Patients With IMDInvasive Mold Diseasecompleted67
2024-04-09P3Amgen AMGNNCT04540497 A Study of Inebilizumab Efficacy and Safety in IgG4- Related DiseaseIgG4 Related Diseaseactive not recruiting135
2024-04-09P1/P2Kronos BioNCT05028751 A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia; Relapsed Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemiaterminated24
2024-04-10P2Gedeon Richter Plc.NCT05322096 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi SyndromePrader-Willi Syndromecompleted39
2024-04-10P3Eli Lilly and Company LLYNCT05362058 A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First TimeDiabetes; Type 2 Diabetescompleted928
2024-04-10 est.P1/P2Biotheus Inc.NCT05867771 A Study of PM1022 in Patients With Advanced TumorsAdvanced Tumorsunknown200
2024-04-11P2US Oncology ResearchNCT02187991 Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerBreast Cancer; Breast Carcinoma; Breast Tumors; Malignant Neoplasm of Breastcompleted169
2024-04-11P3Medeor Therapeutics, Inc.NCT03363945 Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney TransplantsKidney Transplant Rejectioncompleted30
2024-04-11P1/P2UCB Biopharma SRLNCT04393298 A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid TumorsAdvanced Solid Tumorscompleted93
2024-04-11P3GlaxoSmithKlineNCT04718103 A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic PhenotypeAsthmacompleted397
2024-04-11P3Agios Pharmaceuticals, Inc. AGIONCT04770779 A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Transfusion-dependent Alpha-Thalassemia; Transfusion-dependent Beta-Thalassemiaactive not recruiting258
2024-04-11P3Takeda TAKNCT04940624 A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet SyndromeDravet Syndrome (DS)completed144
2024-04-11P2Incyte Corporation INCYNCT04949191 The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.Advanced Malignanciesterminated10
2024-04-11P3Gilead Sciences GILDNCT05079230 Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid LeukemiaAcute Myeloid Leukemiaterminated378
2024-04-11P2Aelis FarmaNCT05322941 Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)Marijuana Abusecompleted333
2024-04-11P3Novo Nordisk A/S NVONCT05365217 A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia BHaemophilia Bcompleted30
2024-04-11P1/P2Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT05762471 Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusOverweight or Obesity; Type2 Diabetes Mellituscompleted142
2024-04-12P2NFL Biosciences SASNCT04571216 Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation TherapySmoking Cessation; Nicotine Dependencecompleted318
2024-04-12P2AstraZeneca AZNNCT05061134 A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionMelanomaactive not recruiting194
2024-04-12P3Intra-Cellular Therapies, Inc.NCT05061706 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderMajor Depressive Disordercompleted480
2024-04-12P1/P2Mustang Bio MBIONCT05360238 Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLFollicular B-cell Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma Recurrent; Mantle Cell Lymphoma Refraterminated20
2024-04-12P2Beijing Suncadia Pharmaceuticals Co., LtdNCT05752461 SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee ArthroplastyPrevention of Venous Thromboembolism After Knee Arthroplastycompleted353
2024-04-12P3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06010693 A Study of Daridorexant in Chinese Patients With Insomnia DisorderInsomnia Disordercompleted206
2024-04-12P3Beijing Minhai Biotechnology Co., LtdNCT06752174 A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated PoliomyelitisPoliomyelitiscompleted300
2024-04-14 est.P3China National Biotec Group Company LimitedNCT05669625 A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella VaccineVaricellaunknown12440
2024-04-15P3Janssen Research & Development, LLCNCT03390504 A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth FacUrothelial Canceractive not recruiting629
2024-04-15P3Merck Sharp & Dohme LLC MRKNCT04195750 A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Carcinoma, Renal Cellactive not recruiting755
2024-04-15P3Incyte Corporation INCYNCT04472429 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).Squamous Cell Carcinoma of the Anal Canalcompleted308
2024-04-15 est.P1/P2OncoResponse, Inc.NCT05094804 A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer AgentsCancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Non Small Cell Luunknown172
2024-04-15P2Verrica Pharmaceuticals Inc. VRCANCT05188729 Open-Label Proof of Concept Study of VP-315 in Basal Cell CarcinomaBasal Cell Carcinoma; Skin Cancer; Cancer of the Skin, Basal Cell; Cancer of the Skin; Carcinomacompleted92
2024-04-15 est.P2OncXerna Theraputics, Inc.NCT05453825 A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid TumorsColorectal Cancer; Triple Negative Breast Cancer; Gastric Cancer; Ovarian Cancerunknown180
2024-04-15P1/P2Enlivex Therapeutics RDO Ltd. ENLVNCT05581719 A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor MalignancySolid Tumor; Peritoneal Metastases; Peritoneal Cancerterminated14
2024-04-15P2Binhui Biopharmaceutical Co., Ltd.NCT05648006 First-line Maintenance of OH2 Injection for Advanced Colorectal CancerAdvanced Colorectal Carcinomaterminated7
2024-04-15P3MediBeaconNCT05777174 Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive RingKidney Diseases; Kidney Injury; Kidney Failurecompleted149
2024-04-15P2ShionogiNCT05925114 Safety and Efficacy Study of S-309309 in Obese AdultsObesitycompleted365
2024-04-16P3Zambon SpANCT03657342 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)Bronchiolitis Obliterans; Chronic Rejection of Lung Transplant; Lung Transplant Rejection; Lung Trancompleted62
2024-04-16P2Crestone, IncNCT04781387 Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile InfectionClostridioides Difficile Infectioncompleted43
2024-04-16P3AstraZeneca AZNNCT05006573 Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis BronchiectasisNon-cystic Fibrosis Bronchiectasisterminated100
2024-04-16P2/P3Shanghai Xinzhi BioMed Co., Ltd.NCT05203679 Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy DrugHemophilia Bactive not recruiting32
2024-04-16P2/P3Boehringer IngelheimNCT05218499 Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated LiposarcomaLiposarcoma, Dedifferentiatedcompleted400
2024-04-16P3Ferring PharmaceuticalsNCT05263388 A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian StimulationInfertilitycompleted302
2024-04-16P2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT05496426 A Study of KL130008 in Adults With Severe Alopecia AreataAlopecia Areataterminated114
2024-04-16P3Colgate Palmolive CLNCT06244303 Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis.Gingivitis; Plaquecompleted82
2024-04-17P2/P3Seagen Inc.NCT04499924 Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal CancerGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinomacompleted17
2024-04-17P2/P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT04856787 A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRCMetastatic Colorectal Cancer (mCRC)terminated62
2024-04-17P2Hoffmann-La RocheNCT05151744 A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular EdemaDiabetic Macular Edemacompleted187
2024-04-17P2Huahui HealthNCT05734807 A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level ViremiaChronic HBV Infectioncompleted74
2024-04-18P2/P3ShireNCT02412787 Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094Hunter Syndromecompleted56
2024-04-18P2Ionis Pharmaceuticals, Inc. IONSNCT03815825 GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular DMacular Degeneration; Geographic Atrophycompleted332
2024-04-18P2AbbVie ABBVNCT04309474 A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic StrokeAcute Ischemic Strokecompleted121
2024-04-18P3Novo Nordisk A/S NVONCT05564117 Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy RangeOverweight; Obesitycompleted307
2024-04-18P2argenx ARGXNCT05633407 Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSPostural Orthostatic Tachycardia Syndromecompleted53
2024-04-18P3Merck Sharp & Dohme LLC MRKNCT05763823 A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant RecipiCytomegalovirus Infectioncompleted120
2024-04-18 est.P2Waterstone Pharmaceutical (Wuhan) Co., LTD.NCT06277128 A Study to Evaluate the Safety and Efficacy of WS016 in Patients With Hyperkalemia.Hyperkalemiaunknown140
2024-04-19P3Exelixis EXELNCT04446117 Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCMetastatic Prostate Cancer; Prostate Adenocarcinomaactive not recruiting575
2024-04-19P2/P3Hoffmann-La RocheNCT04619797 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/CisplatinNon-small Cell Lung Cancer (NSCLC)completed542
2024-04-19P2AstraZeneca AZNNCT05364931 A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic SteatohepatitisNon-cirrhotic Non-alcoholic Steatohepatitis With Fibrosiscompleted54
2024-04-19P2Azafaros B.V.NCT05758922 Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick TypGM2 Gangliosidosis; Niemann-Pick Disease, Type Ccompleted13
2024-04-19P3Alvotech Swiss AG ALVONCT05986786 Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular DiseaseChorioretinal Vascular Diseasecompleted35
2024-04-20P3Annexon, Inc. ANNXNCT04701164 Efficacy and Safety of ANX005 in Subjects With Guillain-Barré SyndromeGuillain-Barre Syndromecompleted242
2024-04-20 est.P2Incyte Biosciences International Sàrl INCYNCT05359692 INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma; Advanced Malignancies; Recurrent Head and Neck Squwithdrawn
2024-04-20 est.P1/P2EgymedicalpediaNCT06239324 Evaluation of Latanoprost Combined With Fractional Erbium- YAG LaserAlopecia Areataunknown70
2024-04-22P3Humacyte, Inc. HUMANCT03183245 Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for HemodialysisRenal Failure; End Stage Renal Disease; Hemodialysis; Vascular Accesscompleted242
2024-04-22P3Taiho Oncology, Inc.NCT04093362 Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene RearrangementsAdvanced Cholangiocarcinoma; FGFR2 Gene Rearrangementsterminated10
2024-04-22 est.P2GlaxoSmithKlineNCT04151225 Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's DiseaseCrohns Disease; Crohn's Diseasewithdrawn
2024-04-22P2Aura Biosciences AURANCT04417530 Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal MUveal Melanoma; Ocular Melanoma; Choroidal Melanomacompleted22
2024-04-22P1/P2S.Biomedics Co., Ltd.NCT04661644 Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients with Critical Limb IschemiaCritical Limb Ischemiacompleted20
2024-04-22P1/P2Gamida Cell ltdNCT05296525 Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHLNon-Hodgkin Lymphomaterminated13
2024-04-22P1/P2iOx TherapeuticsNCT05709821 IMM60 and Pembrolizumab in Melanoma and NSCLCNon-small Cell Lung Cancer; Melanomaterminated1
2024-04-22P2/P3Cara Therapeutics, Inc.NCT05978063 Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia ParestheticaPruritus; Notalgia Parestheticaterminated214
2024-04-23P1/P2UCB Biopharma SRLNCT04643457 A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic DermatitisAtopic Dermatitiscompleted107
2024-04-23P2Boehringer IngelheimNCT05282121 A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic SteatoLiver Diseases; Hypertension, Portalterminated90
2024-04-23P3Handok Inc.NCT05504239 Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and MetforminType 2 Diabetescompleted235
2024-04-23P3UCB Biopharma SRLNCT05681715 A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)Generalized Myasthenia Graviscompleted62
2024-04-23P2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT05702788 Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)COVID-19; Pneumoniawithdrawn
2024-04-24P2Xoft, Inc.NCT04681677 Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and BevacizumabGlioblastoma; Recurrent Glioblastoma; GBM; Recurrent GBMterminated12
2024-04-24P1/P2Endogena Therapeutics, IncNCT05392751 Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis PigmentosaRetinitis Pigmentosa; Retinitis Pigmentosa Syndrometerminated14
2024-04-24P3Eli Lilly and Company LLYNCT05463731 A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)Alzheimer's Diseasecompleted1667
2024-04-24P2RMW TestingNCT06003049 A Study to Evaluate Safety and Efficacy of BOTOX in Adults With Moderate COPDCOPDcompleted40
2024-04-25P1/P2VegaVect, Inc.NCT02317887 Study of RS1 Ocular Gene Transfer for X-linked RetinoschisisRetinoschisis; X-Linkedcompleted12
2024-04-25P2Jounce Therapeutics, Inc.NCT04549025 Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-contaiNSCLCterminated69
2024-04-25P3Takeda TAKNCT04842643 An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency DiseasePrimary Immunodeficiency Diseasecompleted12
2024-04-25P2Gilead Sciences GILDNCT04892446 Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple MyelomaMultiple Myelomaterminated36
2024-04-25 est.P3Incyte Corporation INCYNCT05219864 Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1Hand Eczemawithdrawn
2024-04-25 est.P3Incyte Corporation INCYNCT05233410 Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2Chronic Hand Eczema (CHE)withdrawn
2024-04-25P2Novartis Pharmaceuticals NVSNCT05507437 Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney InjuryAcute Kidney Injury Due to Sepsiscompleted20
2024-04-25P3Atea Pharmaceuticals, Inc. AVIRNCT05629962 SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection); COVID-19completed2285
2024-04-25P3Novartis Pharmaceuticals NVSNCT05795153 A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1Chronic Spontaneous Urticariacompleted144
2024-04-25P2SeqirusNCT05874713 Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in AdultsInfluenza, Human; Infections; Respiratory Tract Infections; Virus Diseases; Infection Viralcompleted480
2024-04-26P1/P2Bristol-Myers Squibb BMYNCT03400332 A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCancer; Melanomacompleted281
2024-04-26P2Novartis Pharmaceuticals NVSNCT04390763 Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal AdenocarMetastatic Pancreatic Ductal Adenocarcinomaterminated164
2024-04-26P3Hoffmann-La RocheNCT04732286 A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular CarcinomaCarcinoma, Hepatocellularterminated100
2024-04-26P2Boehringer IngelheimNCT04876391 A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical TrialHidradenitis Suppurativacompleted45
2024-04-26P3Sedana MedicalNCT05312385 Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive CSedationcompleted277
2024-04-26P3Harbour BioMed (Guangzhou) Co. Ltd.NCT05332210 Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia GravisMyasthenia Graviscompleted111
2024-04-26P2Eisai Co., Ltd.NCT05594589 A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia DisorderSleep Initiation and Maintenance Disorderscompleted65
2024-04-26P2Palatin Technologies, Inc PTNNCT05709444 A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseKidney Diseasecompleted16
2024-04-26P2Novartis Pharmaceuticals NVSNCT05764265 Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension ParticipantsPulmonary Arterial Hypertensionterminated31
2024-04-26P1/P2Inmagene LLCNCT05984784 A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis; ADterminated13
2024-04-26P2SNLD, Ltd.NCT06212089 Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's DiseaseParkinson Diseasecompleted12
2024-04-27 est.P260P Australia Pty LtdNCT05947812 A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With MilCOVID 19 Disease; Mild to Moderate COVID 19 Disease; SARS-CoV-2; Infectious Disease; Severe Acute Reunknown148
2024-04-29P3AstraZeneca AZNNCT03732677 Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCMuscle Invasive Bladder Canceractive not recruiting1063
2024-04-29P1/P2Arvinas Inc. ARVNNCT03888612 Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate CancerProstate Cancer Metastaticcompleted248
2024-04-29P2RECORDATI GROUPNCT04276558 REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult PatientsNeurotrophic Keratitiscompleted108
2024-04-29P2Takeda TAKNCT04278924 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune ThrombocytopeniaPrimary Immune Thrombocytopeniacompleted41
2024-04-29P1/P2Impact Therapeutics, Inc. IBONCT04434482 IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung CancerAdvanced Solid Tumours; Small Cell Lung Cancercompleted59
2024-04-29P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04895345 A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal CarcinomaNasopharyngeal Carcinomacompleted25
2024-04-29P3Arrowhead Pharmaceuticals ARWRNCT05089084 Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)Familial Chylomicronemiacompleted75
2024-04-29P1/P2Hookipa Biotech GmbHNCT05553639 HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate CancerProstate Cancer Metastaticterminated12
2024-04-29P2/P3Pfizer PFENCT05732454 A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth orAtopic Dermatitis; Atopic Dermatitis, Unspecified; Eczema; Eczema, Atopicterminated58
2024-04-30P3CelgeneNCT01476787 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular LymphomaFollicular Lymphomacompleted1030
2024-04-30P1/P2Takeda TAKNCT01506141 An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants WitHunter Syndromecompleted15
2024-04-30 est.P1/P2Stemedica Cell Technologies, Inc.NCT01771679 Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous PhotoagingChronic Effect of Ultraviolet Radiation on Photoaged Skin; Dermatologic Disordersunknown29
2024-04-30P3ACADIA Pharmaceuticals Inc. ACADNCT03121586 Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaSchizophreniaterminated995
2024-04-30P2Incyte Corporation INCYNCT03235544 A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) InhibitorLymphomacompleted162
2024-04-30P2IVIEW Therapeutics Inc.NCT03749317 Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Viral ConjunctivitisAdenoviral Conjunctivitiscompleted135
2024-04-30P1/P2HELP Therapeutics Co., Ltd.NCT03763136 Treating Heart Failure With hPSC-CMsHeart Failurecompleted20
2024-04-30 est.P1/P2CAS Lamvac Biotech Co., Ltd.NCT04165590 Plasmodium Immunotherapy for Advanced Malignant Solid TumorsAdvanced Malignant Solid Tumorunknown60
2024-04-30P1/P2Hutchmed HCMNCT04579757 Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsMetastatic Solid Tumor; Colorectal Cancer; Neuroendocrine Tumors; Small Cell Lung Cancer; Gastric Caterminated87
2024-04-30P1/P2InventisBio Co., LtdNCT04585035 Study to Evaluate D-1553 in Subjects With Solid TumorsSolid Tumor, Adult; NSCLC; CRCunknown180
2024-04-30P2OSE ImmunotherapeuticsNCT04882007 Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative ColitisUlcerative Colitiscompleted136
2024-04-30P2Janssen Research & Development, LLCNCT04882878 A Study of Nipocalimab in Adult Participants With Active Systemic Lupus ErythematosusSystemic Lupus Erythematosuscompleted228
2024-04-30P3Boehringer IngelheimNCT05065190 A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung FibrosisLung Diseases, Interstitialcompleted81
2024-04-30P2/P3Acticor BiotechNCT05070260 ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEboAcute Ischemic Strokecompleted438
2024-04-30 est.P3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT05149326 KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.Advanced Pancreatic Ductal Adenocarcinomaunknown408
2024-04-30 est.P1/P2Shanghai YingLi Pharmaceutical Co. Ltd.NCT05173805 Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS MutationAdvanced Solid Tumorunknown150
2024-04-30 est.P1/P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05207787 Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid TumorsSolid Tumorunknown306
2024-04-30 est.P1/P2Phoenicis TherapeuticsNCT05529134 Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 GeneDystrophic Epidermolysis Bullosaunknown8
2024-04-30P1/P2Medikine, Inc.NCT05716295 A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid TumorsAdvanced or Metastatic Solid Tumorsterminated26
2024-04-30P2Wuhan Createrna Science and Technology Co., LtdNCT06050226 A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Paroxysmal Nocturnal Hemoglobinuriacompleted34
2024-04-30P3Rose Research Center, LLCNCT06088862 Evaluate Harm Reduction Products as a Second Line Intervention for Adult Smokers Who Do Not Quit With NRTSmoking Cessation; Harm Reductionterminated4
2024-04-30P3CanSino Biologics Inc.NCT06120751 A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and OverTetanuscompleted1000
2024-04-30P2Halia Therapeutics, Inc.NCT06241742 Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar ExtractionPaincompleted81

← 2024-03 | 2024-05 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.